Coronary artery ectasia

Article written and reviewed by Dr Luca Moretti

Coronary artery ectasia is pathological diffuse dilation of a coronary artery, conventionally at least 1.5 times wider than the reference vessel and extending over more than one third of its length. Some modern operational definitions use a length greater than 20 mm; diffuse dilation distinguishes it from a focal aneurysm. The criterion used must be stated. An adjacent stenotic segment is not a reliable reference.
Ectasia is not merely a geometric finding. Increased cross-sectional area reduces velocity, promotes vortices and flow separation, prolongs transit, and creates relative stasis. Platelet activation, thrombosis, and distal embolization may result; slow flow may cause ischemia without critical stenosis. Contrast stagnates between beats. Tissue perfusion does not always correspond to luminal patency.

In most adult series, ectasia coexists with atherosclerosis or its risk factors, but it must not automatically be described as a uniform variant of atherosclerosis. Isolated forms, previous vasculitis, Kawasaki disease, congenital anomalies, and connective tissue diseases demonstrate heterogeneous etiology. An epidemiological association does not prove one mechanism. Proposed inflammatory biomarkers are not diagnostic. The cause is reconstructed individually.
Detection varies from less than 1 percent to a few percentage points of coronary angiograms, chiefly because populations, methods, and definitions differ. The right coronary artery is most frequently affected, and men predominate in historical cohorts; angiographic prevalence is not population prevalence. Patients studied already have a clinical indication. Series combining aneurysms and ectasia overstate their comparability.

No antithrombotic treatment is universally validated for ectasia alone. Observational studies and meta-analyses of nonrandomized data suggest differences among no therapy, aspirin, dual antiplatelet therapy, and anticoagulation, but confounding by indication and heterogeneous populations preclude automatic prescriptions. Therapeutic uncertainty must be explicit. ACS and stents follow their own guidelines. Bleeding risk remains essential to the decision.
Ectasia must also be distinguished from coronary slow-flow syndrome, defined by delayed contrast progression without significant stenosis and not necessarily accompanied by dilation. The phenotypes may coexist but involve different anatomical and microvascular determinants; hemodynamic terminology prevents improper inference. Slow flow describes behavior, not etiology. Ectasia instead describes measurable vascular geometry.

Etiology, risk factors, pathogenesis, and pathophysiology

Histology of advanced forms shows rarefaction or destruction of the media and elastic lamina, loss of smooth muscle cells, and degradation of collagen and elastin. Chronic expansion reflects an imbalance between matrix synthesis and proteolysis; musculoelastic weakness permits pressure-driven remodeling. Routine clinical coronary biopsy does not exist. Histological observations derive from autopsies and selected surgical specimens.
In atherosclerosis, lipids, macrophages, metalloproteinases, oxidative stress, and remodeling may weaken the media as the vessel expands to accommodate plaque. Only part of this continuum exceeds the conventional ectasia threshold; positive remodeling is therefore related but not synonymous. Stenoses and dilation may alternate within one vessel. Atherosclerotic prevention follows the overall burden.

Smoking, hypertension, and dyslipidemia are frequently represented in cohorts, whereas several studies show an inverse association between diabetes and ectasia despite diabetes increasing general atherosclerotic risk; this observation does not imply clinical protection and may reflect differences in remodeling, selection, or confounding. Diabetes mellitus remains a cardiovascular determinant. A metabolic condition is never encouraged. Associations do not define individual causality.
Metalloproteinases, cytokines, endocan, uric acid, and many other markers have been associated with ectasia in small cross-sectional studies. Alpha-1 antitrypsin deficiency has also been proposed through reduced elastase inhibition; experimental biomarkers lack diagnostic validation. Many studies measure associations after disease appears. No blood value is used to classify extent.

Kawasaki disease may leave diffuse dilations or multiple aneurysms persisting into adulthood, often with calcification and late stenosis. A childhood history of fever and mucocutaneous signs may not be remembered; previous Kawasaki disease should be considered in young people with proximal lesions. Original Z scores may be unavailable. Distribution, calcification, and pediatric records aid attribution.
Polyarteritis nodosa, Behçet disease, Takayasu arteritis, and other vasculitides may produce dilation, but the phenotype is often focal or mixed rather than uniform ectasia. Vasculitic activity requires systemic evidence and wall or other-territory imaging; an inflammatory cause is not inferred from shape alone. Normal CRP does not exclude a healed lesion. Immunosuppression is reserved for a sound diagnosis.

Congenital forms may accompany fistulas, anomalies of origin, or familial arteriopathies. Aortic or other arterial dilation is more frequent in some ectasia cohorts, suggesting systemic wall predisposition in subgroups; multiterritorial disease merits imaging guided by signs. It does not justify indiscriminate whole-body screening. A family history of aneurysms guides selective genetic counseling.
Within an ectatic segment, maintaining flow would require velocity to decrease in proportion to the increased area. Curves, bifurcations, and abrupt caliber changes generate vortices and local retrograde flow; flow dispersion prolongs wall contact. Contrast may oscillate back and forth; these features promote stasis without automatically demonstrating thrombus.

Thrombosis results from the interaction of stasis, an altered wall, and systemic factors. Mural thrombus may narrow the lumen, fragment, or embolize into the microcirculation; repeated small events may cause ischemia or necrosis; ectatic thrombogenicity varies among patients. Diameter, length, and slow flow are clues, not validated thresholds. Previous ACS and documented thrombus carry more weight than an isolated finding.
Wall stress and endothelial shear stress change with diameter, curvature, and pulsatility. Regions of low or oscillatory shear may promote proinflammatory and prothrombotic endothelial phenotypes, but computational models have not produced usable clinical thresholds; flow mechanics explains intravascular heterogeneity. It is not measured during ordinary angiography. A virtual model does not replace documented events and anatomy.

Pathological anatomy, classification, and progression

Ectasia is defined relative to an adjacent normal segment, but diffuse disease may offer no internal reference. In such cases, the expected segment, contralateral vessel, or contextual anatomical data are used, with uncertainty documented; the comparative measurement must be reproducible. Pharmacological vasodilation modestly changes caliber. Images after nitrate may standardize invasive comparison.
The Markis classification describes angiographic extent. Type I is diffuse ectasia of two or three coronary arteries; type II, diffuse ectasia of one artery and localized dilation of another; type III, diffuse ectasia of one vessel; and type IV, localized or segmental dilation; Markis type I represents the greatest extent. Type IV overlaps modern aneurysm definitions, so actual morphology must also be reported.

The classification does not quantify maximum diameter, thrombus, flow, stenosis, or myocardial territory and was not designed as a treatment algorithm. A type III lesion with thrombus may be more dangerous than stable type I; the Markis class does not replace risk stratification. Recent studies use it as a measure of distribution. No treatment is mandatory for any one type.

Markis angiographic classification

• Type I: diffuse ectasia of two or three coronary arteries.
• Type II: diffuse ectasia of one coronary artery and localized dilation of another.
• Type III: diffuse ectasia confined to a single coronary artery.
• Type IV: localized or segmental dilation, now often described as a focal aneurysm.

The right coronary artery frequently shows the most extensive forms, probably because of geometry and flow patterns, while the left anterior descending and circumflex arteries may be affected alone or together. Isolated left main ectasia is rare; vessel distribution influences thrombosis and PCI feasibility. A large right coronary artery may contain substantial thrombus. Distal diameter influences stent selection.
Angiography shows delayed filling, stasis, turbulence, incomplete opacification, and delayed washout. TIMI flow grade qualitatively describes flow, while corrected TIMI frame count measures the frames needed to reach distal landmarks; frame count depends on heart rate and technique. It is not specific to ectasia. Microvascular disease and injection pressure may alter it.

The wall may contain plaque, calcium, medial thinning, and layered thrombus. IVUS has shown that segments appearing smooth on luminography may harbor a high atherosclerotic burden. Wall heterogeneity precludes assuming healthy arteries. OCT penetrates less effectively in large cavities and red thrombus. CCTA better depicts external diameter and overall length.
Natural history is not defined by large prospective cohorts. Some ectasias remain stable, others develop thrombus or coexist with stenotic progression; how often diameter truly increases over time is unclear; anatomical progression requires comparable measurements. A different cardiac phase may change apparent caliber. Lack of growth does not eliminate thrombotic risk.

Isolated ectasia means absence of significant obstructive stenosis, not absence of wall atherosclerosis or microvascular dysfunction; this definition distinguishes a useful research subgroup, not one mechanism; an isolated form may still cause angina or ACS. Prognosis is generally better than with multivessel stenosis, but must not be described as invariably benign.
An ectatic vessel may have abrupt transitions to normal or stenotic segments; these discontinuities concentrate vortices and may create proximal or distal areas of stasis, while the microvascular bed receives irregular pulsatile flow; transition zones deserve procedural attention. An outlet stenosis may increase stasis. An inlet stenosis may mask true diameter during injection.

Clinical manifestations

Ectasia may be entirely asymptomatic and identified during CCTA or coronary angiography performed for another reason. Dilation does not prove that chest pain results from ischemia; an incidental finding requires description, not automatic alarm. Plaque and stenoses are assessed; symptoms and cardiovascular risk determine subsequent tests.
Exertional angina may result from associated obstructive disease or from slow flow, microembolization, and reduced ability to increase perfusion. Some patients with isolated ectasia show inducible ischemia despite no stenosis; the cause of angina must be demonstrated. Vasospasm and microvascular dysfunction may coexist. A positive functional test alone does not identify the compartment.

Resting pain with elevated troponin may result from in situ thrombosis or embolization, producing STEMI, NSTEMI, or MINOCA according to residual anatomy and findings. Thrombus may dissolve before angiography, leaving only ectasia and slow flow; an acute coronary syndrome requires immediate treatment. Ectasia does not exclude concomitant plaque rupture. Intravascular imaging may identify the substrate.
Dyspnea, fatigue, and reduced exercise tolerance may be ischemic equivalents or consequences of previous infarction. They are nonspecific and require investigation for heart failure, anemia, pulmonary disease, and deconditioning; ventricular function is measured by echocardiography. Magnetic resonance imaging identifies unrecognized scars. Chronic symptoms must not be attributed to diameter without correlation.

Palpitations and syncope are not direct manifestations of dilation but may follow ischemia, infarction, or scar. Syncope during pain requires ECG monitoring and urgent assessment; arrhythmic risk depends chiefly on myocardial damage. Isolated ectasia does not indicate a defibrillator; neurological, orthostatic, and vasovagal causes remain in the differential.
During angiography, contrast stagnation and delayed washout visually express abnormal flow. The patient may nevertheless be asymptomatic and show no ischemia on testing; a slow-flow phenotype does not always equal primary coronary slow-flow syndrome. The latter may occur in nondilated vessels; precise terminology avoids conflating pathophysiologically different conditions.

In young people, recurrent events without atherosclerotic factors require investigation for previous Kawasaki disease, vasculitis, connective tissue disease, and congenital anomalies. In older people, atherosclerosis and common causes remain more likely without excluding other mechanisms; pretest probability guides etiologic testing. Indiscriminate autoimmune panels produce false positives. Childhood history and extracoronary imaging may be decisive.
Quality of life may be impaired by recurrent angina, hospital visits, and therapeutic uncertainty. Defining a plan for acute symptoms and follow-up reduces both underestimation and excessive medicalization; symptom management requires measurable goals. A negative test does not invalidate pain; alternative diagnoses must be addressed without abandoning cardiovascular assessment.

The clinical presentation may change over time. A previously stable patient who develops longer-lasting pain, pain at rest, or pain associated with dyspnea and sweating must be assessed for possible ACS regardless of the known diagnosis; a change in pattern takes priority over the previous label. ECG and troponin are obtained promptly. Response to nitrate does not exclude evolving thrombosis.

Investigations and diagnosis

Anatomical diagnosis requires measurement of diameter and length, identification of a reference, number of vessels, stenoses, thrombus, and flow pattern. Ectasia should not describe any slight irregularity or a short post-stenotic dilation; a standardized definition improves comparability. The report states whether the lesion is diffuse. A Markis category is added without replacing measurements.
CCTA visualizes the entire coronary tree, external diameter, plaque, calcium, and mural thrombus. Curved reconstructions permit measurement of length and distinction among ectasia, serial aneurysms, and post-stenotic dilation; coronary tomography is useful for selected anatomical follow-up. A high heart rate and calcification reduce quality. Iodinated contrast and radiation require an appropriate indication.

Invasive coronary angiography remains essential for ACS, high-risk ischemia, or a PCI indication. It shows filling, stasis, TIMI flow, collaterals, and stenoses, but the opacified lumen may underestimate a wall filled with thrombus; dynamic assessment is its strength. Repeated injections increase contrast and radiation. Thrombus burden must be sought actively.
Corrected TIMI frame count quantifies contrast progression to a distal landmark, correcting for the greater length of the left anterior descending artery. High values indicate delayed flow but not its cause; TIMI frame count is influenced by technique. Pressure, heart rate, and the microcirculation alter the result. It is mainly useful for comparison and research, not as an autonomous treatment threshold.

IVUS measures the external elastic membrane, lumen area, plaque, and thrombus and may guide stenting in a vessel of variable diameter. OCT defines the surface and stent at high resolution, but large calibers require much contrast for lumen clearance and exceed optical penetration. Intracoronary imaging is selective. It is not performed merely to confirm evident ectasia. It becomes valuable when it changes the procedure.
Echocardiography assesses ventricular function, motion, valves, and the aorta; it may visualize proximal coronary arteries in children and patients with Kawasaki disease. It is insufficient to map distal adult ectasia; cardiac assessment seeks consequences and associations. A dilated aorta may suggest systemic arteriopathy; a normal echocardiogram does not exclude coronary disease.

Stress echocardiography, SPECT, PET, or stress magnetic resonance imaging documents ischemia and territory, especially without clearly significant stenoses. PET and MRI may quantify or estimate global reserve and identify concomitant microvascular dysfunction; functional testing guides symptom therapy. It does not precisely predict aneurysmal thrombosis. The method is selected according to the patient and availability.
Cardiac magnetic resonance imaging characterizes scar, edema, function, and perfusion, helping distinguish infarction, myocarditis, and Takotsubo syndrome in MINOCA presentations. Dedicated coronary visualization is possible proximally but less detailed than CCTA; the scar pattern confirms ischemic injury. Embolic infarction may be multifocal. Absence of enhancement does not exclude transient ischemia.

Etiologic tests are selected. Lipids, glucose, blood pressure, and smoking define atherosclerotic risk; inflammatory markers, ANCA, autoantibodies, or IgG4 are requested only with systemic evidence; childhood fever and proximal aneurysms suggest Kawasaki disease; the causal work-up avoids random panels. Aortic imaging is indicated when appropriate signs exist. An isolated biomarker does not classify the coronary artery.
The differential diagnosis includes focal aneurysm, post-stenotic dilation, fistula, positive remodeling, vein graft, congenital anomaly, and projection artifact. Primary slow-flow syndrome may delay contrast without dilation; morphological distinction precedes the label. An aneurysm requires assessment of the neck and wall. Ectasia requires longitudinal measurement of involvement.

When thrombus is identified, the report should specify its location, mobility, degree of organization, and relationship to branches and stenoses. CCTA shows mural components, while IVUS and OCT may be limited by caliber, thrombus, and procedural risk; the thrombotic map guides treatment and surveillance. A simple contrast defect may be artifact. Multimodal confirmation is useful if it changes antithrombotic therapy.

Treatment and prognosis

There are no dedicated guidelines based on large randomized trials for ectasia. Treatment is constructed from the clinical syndrome, concomitant atherosclerosis, thrombus, event history, and bleeding risk; personalized management does not mean arbitrary care. ACS, stents, and atrial fibrillation follow validated recommendations. Markis class alone does not prescribe a drug.
Smoking cessation, blood pressure control, physical activity, and treatment of diabetes and lipids are indicated according to overall cardiovascular risk. A statin is appropriate for atherosclerosis or a preventive indication but is not proven specific therapy for every nonatherosclerotic ectasia; atherosclerotic risk control reduces common events. It is not known to reduce ectatic diameter. Targets follow cardiovascular guidelines.

Aspirin is often used when atherosclerotic coronary disease or a previous event coexists. A recent network meta-analysis of mainly observational studies ranked DAPT and aspirin favorably versus no treatment, but heterogeneity and confounding preclude a universal recommendation. Antiplatelet evidence remains indirect. DAPT increases bleeding. Duration and selection chiefly follow ACS and PCI.
Anticoagulation may be considered in patients with thrombus, diffuse ectasia and marked slow flow, recurrent events despite appropriate therapy, or another formal indication. Evidence is insufficient to anticoagulate every patient; anticoagulant selection weighs recurrence and bleeding. Warfarin has more historical experience. DOAC data are limited, and the drugs are not automatically equivalent.

Combining an anticoagulant with antiplatelet drugs increases bleeding and requires explicit indications, a defined duration, and reassessment. A high D-dimer or Markis class alone is not a validated international criterion; the thrombosis-bleeding balance changes over time. Age, renal function, and previous bleeding are determinants. Gastroprotection and adherence are considered when appropriate.
Angina is treated according to mechanism. Beta-blockers may prolong diastole and reduce demand in selected patients, while calcium channel blockers are useful when vasospasm coexists; no class has been shown to correct ectasia; antianginal therapy is titrated to symptoms. Blood pressure and heart rate limit doses. Vasomotor provocation may clarify concomitant phenotypes.

Nitrates may relieve an associated stenosis or spasm, but in some patients with isolated ectasia they increase dilation and worsen ischemia from maldistributed flow. They are therefore not prescribed automatically for every pain; response to nitrates must be observed individually. Worsening requires reassessment. Sublingual nitrate does not replace urgent evaluation for prolonged pain.
During ACS with a large thrombus, anticoagulation, potent antiplatelet therapy, and PCI are adapted to burden and flow. Selective thrombus aspiration, intracoronary vasodilators, or deferred strategies may help, but routine aspiration is not recommended for every STEMI; no-reflow must be prevented and treated. A stent covers the culprit lesion, not all ectasia. Imaging guides sizing and apposition.

PCI is technically difficult because diameter varies, landing zones are wide, and thrombus may be abundant. An undersized stent remains malapposed; an oversized stent may damage the wall; intravascular sizing reduces uncertainty. Significant focal stenoses may be treated without excluding the entire vessel. Bifurcations and distal flow determine strategy.
Bypass is considered for complex multivessel disease, stenoses unsuitable for PCI, or ectatic segments with surgically manageable anatomy. Ectasia alone without ischemia is not an indication; surgical revascularization requires an adequate distal bed. Native flow may compete with the graft; ligation or exclusion is decided only in selected cases.

Follow-up monitors symptoms, adherence, bleeding, new events, and ventricular function. Serial imaging is reserved for clinical changes, thrombus, progressive causes, or questions capable of changing management; appropriate surveillance avoids radiation without benefit. There is no universal interval; a stable measurement does not justify stopping therapy indicated for previous infarction.
Prognosis depends greatly on concomitant obstructive coronary disease. Studies in patients with infarction associate ectasia with more recurrent events, while cohorts with isolated forms show a more favorable but not ACS-free course; prognostic risk is therefore contextual. Extent, slow flow, and thrombus add information. Markis class alone does not provide an individual probability.

Therapeutic reassessment must be especially rigorous after an event-free period. Lack of recurrence may reflect treatment efficacy, low intrinsic risk, or both and does not prove that combined antithrombotic therapy remains necessary; reasoned deprescribing considers the original indication and bleeding. It is not undertaken without supervision. New anatomical or clinical data may instead justify intensification.

Complications

In situ thrombosis may form slowly as mural material or acutely occlude the vessel. Potential volume is large in markedly dilated segments, and thrombus may extend into branches; ectatic thrombosis may recur. Delayed angiography may show only remnants. CCTA or IVUS helps estimate the nonopacified burden.
Distal embolization of platelets and fibrin produces microvascular occlusions, small or extensive infarctions, and no-reflow. During PCI, manipulation may release more material; microvascular perfusion may remain impaired after epicardial opening. Blush, ST segments, and MRI assess different consequences; embolic protection is not available for every anatomy.

Recurrent ischemia without stenosis may result from slow flow, transient thrombi, or concomitant mechanisms. Repeated visits and discordant tests are common when the anatomical finding is treated as the sole explanation; recurrent angina requires renewed phenotyping. Vasospasm and CMD may be tested in expert centers. Noncardiac pain may coexist with true ectasia.
An extensive infarction causes remodeling, ventricular dysfunction, mitral regurgitation, and heart failure. Subsequent prognosis depends more on function and scar than on isolated coronary diameter; ventricular remodeling requires guideline-based therapy. Rehabilitation improves capacity and adherence; recurrence prevention encompasses all cardiovascular factors.

Acute ischemia and scar may cause ventricular tachycardia or fibrillation, syncope, and sudden death. There are no data for ectasia-specific arrhythmic prophylaxis without myocardial damage; the arrhythmic substrate is documented with ECG and imaging. Monitoring follows symptom frequency; defibrillator implantation and electrophysiological study follow ordinary indications.
PCI may be complicated by embolization, no-reflow, malapposition, stent thrombosis, restenosis, and branch occlusion. Progressive dilation around a stent may create acquired malapposition; a stent complication requires intravascular imaging. New DAPT does not correct a serious mechanical problem; revision depends on cause and anatomy.

Antithrombotic therapy may cause gastrointestinal, intracranial, or procedural bleeding, especially when anticoagulation and DAPT are combined. Limited robust evidence makes avoidance of indefinite treatment without reassessment particularly important; bleeding risk is part of net outcome. Renal function and interactions change exposure. Every bleed mandates review, not unsupervised discontinuation.
The main conceptual complication is attributing every symptom to ectasia or, conversely, always considering it benign. Balanced assessment integrates anatomy, flow, ischemia, thrombus, and general risk while acknowledging evidence limitations; diagnostic precision prevents opposite excesses. The patient must know warning signs. Follow-up and therapy adapt to events and new data.

A further consequence is repeated exposure to procedures and contrast when symptoms are not phenotyped. Serial CCTA and angiography without a question capable of changing management may accumulate radiation, nephrotoxicity, and vascular complications. Imaging appropriateness is part of safety. Clinical follow-up may suffice in stable cases. A new event or progressive cause instead changes the threshold.